Primary care visits are higher amongst adults who report sexual dysfunction concerns after cancer treatment Authors: Robin Urquhart, Patience Nishimagizwe, Lynn Lethbridge, Cynthia Kendell Published: 2026 ABSTRACT Sexual health concerns are prevalent ongoing effects after cancer treatment. This study examined the association between sexual dysfunction and physician use among adult cancer survivors in Nova Scotia, Canada. We identified all adult survivors of breast, prostate, colorectal, melanoma, and hematological cancers, and all young adult cancer survivors of any invasive cancer, who were diagnosed between 2012 and 2014 from the Nova Scotia Cancer Registry (NSCR). Sexual dysfunction concerns were obtained from the Cancer Transitions Survey using a single question (“How much was this a concern for you?”). This national survey, administered in 2016, explored the experiences of cancer survivors 1–3 years post-cancer treatment. Survey responses were linked to the NSCR and administrative health databases to capture healthcare utilization. Multivariable Poisson and negative binomial regression models examined the association between sexual dysfunction and the number of primary care and oncology specialist visits, respectively, during follow-up care. 823 respondents were included in this study (46% male, 54% female). Nearly one-third (32.4%) of respondents indicated sexual dysfunction was a big or moderate concern at the time of survey completion. During routine follow-up, cancer survivors with self-reported sexual dysfunction had a 9% higher rate of primary care visits compared to those without sexual dysfunction (IRR 1.09, 95% CI 1.06–1.13, p < 0.0001). No significant association was observed between self-reported sexual dysfunction and oncology visits. These findings highlight a potentially important role for primary care providers in addressing sexual health concerns in their cancer survivor patients. Primary care providers should be supported with appropriate resources and training to optimize survivors’ sexual health and recovery after cancer.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55735-y. Introduction Worldwide, the prevalence of cancer survivors continues to grow, reflecting important advances in both early detection and treatment1. In 2018, it was estimated that more than 1.5 million Canadians were living with or beyond cancer, with breast, prostate, and colorectal cancers accounting for nearly half (48.5%) of these cancers2. Many of these individuals experience substantial ongoing needs due to their cancer and/or its treatment3,4. Sexual function is one aspect of health that is negatively affected by many cancer treatments. In fact, the prevalence of sexual dysfunction after cancer treatment has been reported to range from 30 to 100%, affecting both males and females5,6. For example, a recent meta-analysis examining females treated for breast cancer reported that nearly three-quarters met the diagnostic criteria for female sexual dysfunction7. In males who underwent surgery for prostate cancer, 95% reported substantial erectile dysfunction at 6 months post-treatment8, while 93% of males who were treated with multiple therapies for rectal cancer reported a negative impact on erections9. For both males and females, common challenges with sexual health after cancer treatment involve disorders of sexual response (e.g., arousal, erectile dysfunction) as well as sexual desire and motivation10. Unfortunately, the evidence suggests that, without intervention, these challenges negatively impact quality of life and can last for years or decades after completing cancer treatment11–17. Despite the high prevalence of sexual health concerns after cancer treatment, patients report their concerns in this domain are infrequently discussed or addressed18,19. In fact, only a minority of patients are ever asked about their sexual health concerns20–23, yet report a desire for these conversations with their providers23,24. Men are more likely to be asked than women23,25, with a recent study at a radiation oncology clinic finding that 53% of men reported they were asked about their sexual function compared to only 22% of women23. Both oncologists and primary care providers self-report infrequent discussions of sexual health issues with their patients26,27. Barriers to initiating sexual health discussions range from a lack of education and/or confidence around sexual health to a lack of clarity as to which member of the healthcare team is responsible for these conversations28–30. Although the prevalence of sexual dysfunction concerns in cancer survivors is high and often persistent, there is scant literature examining whether and how cancer survivors with sexual dysfunction use healthcare services after cancer treatment and during routine follow-up care. The objective of this study was to examine the association between sexual dysfunction and physician use among adult cancer survivors in Nova Scotia, Canada, after they have completed cancer treatment. Methods Study design and population This study employed a retrospective cohort design, linking cross-sectional survey data to population-based administrative health data. The study population was comprised of two sub-populations derived from the survey (see below). The first was adults (30 + years) diagnosed with breast, prostate, colorectal, melanoma, or haematological cancer in the province of Nova Scotia between May 2, 2012, and May 2, 2014. Individuals diagnosed with stage IV breast, prostate, colorectal, melanoma, or haematological cancer were excluded from the survey. The second was young adults (18–29 years) diagnosed between May 2, 2012 and May 2, 2014 and received a primary diagnosis of any invasive cancer. Individuals who were diagnosed with stage IV disease at diagnosis (except for testicular cancer) or who were diagnosed with non-melanoma skin cancer or Kaposi’s sarcoma were excluded. The distinction between the two sub-populations was made for two reasons: (1) the literature suggests these sub-populations experience differences in needs post-treatment as well as care experiences, and (2) differences in cancer types/diagnoses across the two sub-populations. Despite this distinction, the survey and data collection procedures were the same for both sub-populations. All individuals were identified from the Nova Scotia Cancer Registry (NSCR) using International Classification of Diseases (ICD) and topography codes. All survey respondents consented to have their survey data linked to administrative health data for future research purposes. Data sources The source of the survey data was the “Cancer Transitions Survey”, a population-based survey administered in 2016 across all ten Canadian provinces. This 83-item survey was developed based on previously validated surveys31,32 and in consultation with subject matter experts and people with lived cancer experience. The survey was administered by provincial cancer registries. The intent of the survey was to examine survivors’ experiences and needs after completing cancer treatment, factors impacting those needs, and strategies to address needs. This is why individuals diagnosed with stage IV cancers (except for testicular) were excluded from the survey population. Survey development and sampling approaches are described in detail elsewhere3,33. This investigation focused on those who responded from Nova Scotia only. The NSCR sent the survey, via postal mail, to every individual in Nova Scotia who met the eligibility criteria (n = 3492). Recipients were able to complete the paper version of the survey or use a unique identifier to complete the survey electronically. The survey response rate was 44.6%. The survey dataset was linked to six administrative health datasets in Nova Scotia: the NSCR, which provided comprehensive data on cancer type, diagnosis date, stage at diagnosis, date of death, and cancer history; the Oncology Patient Information System, which provided data on treatments received as well as information allowing us to determine cancer recurrence; the Medical Services Insurance Insured Patient Registry, which provided data to confirm the person was enrolled in the provincially funded health insurance program and to identify dates of enrollment/disenrollment; the Medical Services Insurance Physician Billings, which provided physician claims data; the Canadian Institute for Health Information’s (CIHI) Discharge Abstract Database (DAD), which provided data on hospitalizations including diagnoses and procedures; and the CIHI National Ambulatory Care Reporting System (NACRS), which provided data for ambulatory visits and services. From all datasets, we acquired data until December 31, 2019 to ensure 4 full years of follow-up data for each survey respondent. Study variables Sexual dysfunction was obtained from the Cancer Transitions Survey dataset. Sexual dysfunction concerns (yes/no, where yes = moderate/big concern and no = low/no concern) were assessed using a single question (“How much was this a concern for you?”) with four possible responses: not a concern, small, moderate, or big. This was self-reported at one timepoint (1–3 years post-treatment). Table 1 presents the socio-demographic and disease covariates used in the analyses. Table 1Study variables.VariableCategoriesData SourceAge at survey completion18–54, 55–64, 65–74, 75+Transitions surveySexMale, femaleTransitions surveyChronic conditions0, 1+Transitions surveyPlace of birthCanada, otherTransitions surveyMarital statusMarried/partnered, notTransitions surveyHighest education attainedLess than a high school diploma, high school, some post-secondary, certificate/diploma, degreeTransitions surveyLanguage spoken most often at homeEnglish/French, otherTransitions surveyCancer typeHematologic, breast, colorectal, melanoma, prostate, otherCancer registryStage at diagnosisI, II, IIICancer registryPlace of residenceaRural, urbanCancer registryaPlace of residence was categorized as rural or urban based on the respondent’s postal code at diagnosis; in Canada, when the second digit of the postal codes equals 0, this indicates rural residence. Table 1Study variables.VariableCategoriesData SourceAge at survey completion18–54, 55–64, 65–74, 75+Transitions surveySexMale, femaleTransitions surveyChronic conditions0, 1+Transitions surveyPlace of birthCanada, otherTransitions surveyMarital statusMarried/partnered, notTransitions surveyHighest education attainedLess than a high school diploma, high school, some post-secondary, certificate/diploma, degreeTransitions surveyLanguage spoken most often at homeEnglish/French, otherTransitions surveyCancer typeHematologic, breast, colorectal, melanoma, prostate, otherCancer registryStage at diagnosisI, II, IIICancer registryPlace of residenceaRural, urbanCancer registryaPlace of residence was categorized as rural or urban based on the respondent’s postal code at diagnosis; in Canada, when the second digit of the postal codes equals 0, this indicates rural residence. Study variables. aPlace of residence was categorized as rural or urban based on the respondent’s postal code at diagnosis; in Canada, when the second digit of the postal codes equals 0, this indicates rural residence. All healthcare utilization variables were acquired from administrative health data. There were two outcomes of interest: first, the number of follow-up visits to oncology specialists and second, the number of follow-up visits to primary care. The latter were categorized into “cancer-specific”, “non-cancer”, and “all” visits, with cancer-specific visits defined as any visit containing a diagnosis code corresponding to “neoplasm” (i.e., ICD-9 codes 140 to 239 inclusive). All visits were obtained from the Medical Services Insurance Physician Billings database. The follow-up period began one year after the diagnosis date in the NSCR and continued for four years (the end of the study period). Analyses The final cohort for this study excluded respondents with evidence of recurrence or who had died, who did not have a specialist appointment at any point after their cancer diagnosis (e.g., a respondent diagnosed with early-stage melanoma who may have seen their primary care provider for excision only), or who had missing survey values. Patients were excluded if they had evidence of cancer recurrence because we were specifically interested in sexual dysfunction concerns in the follow-up care period. Complete case analyses were used due to missing data in the survey dataset. Descriptive statistics were computed to describe the study cohort, stratified by those who reported concerns with sexual dysfunction and those who did not. Univariable and multivariable regression models for count data were run to test whether concerns with sexual dysfunction were associated with the number of physician visits (oncologist and primary care) during the follow-up period. Specifically, Poisson regression was used, with negative binomial regression for outcomes that had an overdispersion of zeros. These models were run for all participants and then separately for males and females. Covariates in the multivariable models included age at survey completion, sex, cancer type, stage at diagnosis, marital/partnered status, chronic conditions, rural residence, place of birth (Canada, not born in Canada), highest education attained, and language spoken most often in the home setting. Incidence rate ratios (IRR) were reported and a confidence level of 95% used to determine statistical significance. SAS version 9.4 was used to complete all analyses. Results Although 1514 individuals responded to the survey, the final cohort for this study included 823 individuals. Specifically, respondents with evidence of recurrence and/or who died (n = 179), who did not have a specialist appointment at any point after their cancer diagnosis (n = 222), or who had missing survey values (n = 290) were excluded. Altogether, 32.4% of respondents indicated sexual dysfunction was a big or moderate concern at the time of survey completion (1–3 years after completing cancer treatment). A higher percentage of males reported concerns with sexual dysfunction compared to females (47.4% and 19.6%, respectively). Younger individuals reported higher levels of sexual dysfunction concerns: for example, 42.6% of respondents aged 18–54 reported concerns with sexual dysfunction while 26.3% of those aged 75 + reported concerns with sexual dysfunction. Among cancer types, the percentage of respondents reporting concerns with sexual dysfunction ranged from 6.9% (melanoma) to 63.1% (prostate cancer). A higher percentage of respondents who were married/partnered reported concerns with sexual dysfunction compared to those who were not married/partnered (36.2% and 19.2%, respectively). Table 2 describes the study cohort, stratified by those who reported sexual dysfunction concerns and those who did not. Table 2Cohort characteristics in 823 patients diagnosed with cancer in Nova Scotia and who were 1–3 years post-treatment at the time of survey administration, stratified by sexual dysfunction concerns.SurvivorsYESn (%)NOn (%)267 (32.4%)556 (67.6%) Sex Male180 (47.4%)200 (52.6%)Female87 (19.6%)356 (80.4%) Age at survey completion Age 18–5449 (42.6%)66 (57.4%)Age 55–6489 (41.4%)126 (58.6%)Age 65–7488 (26.1%)249 (73.9%)Age 75+41 (26.3%)115 (73.7%) Cancer type Hematologic8 (25.8%)23 (74.2%)Breasta69 (22.5%)238 (77.5%)Colorectal32 (19.5%)132 (80.5%)Melanoma5 (6.9%)67 (93.1%)Prostateb147 (63.1%)86 (36.9%)Otherc6 (37.5%)10 (62.4%) Stage at diagnosis Stage I63 (18.6%)275 (81.4%)Stage II129 (40.7%)188 (59.3%)Stage III75 (44.6%)93 (55.4%)Rural residence88 (30.3%)202 (69.7%)Any chronic condition31 (30.4%)71 (69.6%) Marital status Married/partnered202 (36.2%)409 (63.8%)Not married/partnered35 (19.2%)147 (80.8%) Education attained Less than high school diploma45 (29.4%)108 (70.6%)High school diploma48 (29.8%)113 (70.2%)Some post-secondary education61 (38.1%)99 (61.9%)Post-secondary certificate46 (30.9%)103 (69.1%)Post-secondary degree47 (34.2%)52 (65.8%)Speaks English or French most often267 (32.6%)553 (67.4%)Born in Canada244 (32.1%)517 (67.9%)aAll breast cancer patients are female.bAll prostate cancer patients are male.cOther category = patients aged 18–29 at diagnosis with a primary diagnosis of any invasive cancer, excluding: (1) stage IV at diagnosis (except for testicular cancer); (2) non-melanoma skin cancer; and (3) Kaposi’s sarcoma. Table 2Cohort characteristics in 823 patients diagnosed with cancer in Nova Scotia and who were 1–3 years post-treatment at the time of survey administration, stratified by sexual dysfunction concerns.SurvivorsYESn (%)NOn (%)267 (32.4%)556 (67.6%) Sex Male180 (47.4%)200 (52.6%)Female87 (19.6%)356 (80.4%) Age at survey completion Age 18–5449 (42.6%)66 (57.4%)Age 55–6489 (41.4%)126 (58.6%)Age 65–7488 (26.1%)249 (73.9%)Age 75+41 (26.3%)115 (73.7%) Cancer type Hematologic8 (25.8%)23 (74.2%)Breasta69 (22.5%)238 (77.5%)Colorectal32 (19.5%)132 (80.5%)Melanoma5 (6.9%)67 (93.1%)Prostateb147 (63.1%)86 (36.9%)Otherc6 (37.5%)10 (62.4%) Stage at diagnosis Stage I63 (18.6%)275 (81.4%)Stage II129 (40.7%)188 (59.3%)Stage III75 (44.6%)93 (55.4%)Rural residence88 (30.3%)202 (69.7%)Any chronic condition31 (30.4%)71 (69.6%) Marital status Married/partnered202 (36.2%)409 (63.8%)Not married/partnered35 (19.2%)147 (80.8%) Education attained Less than high school diploma45 (29.4%)108 (70.6%)High school diploma48 (29.8%)113 (70.2%)Some post-secondary education61 (38.1%)99 (61.9%)Post-secondary certificate46 (30.9%)103 (69.1%)Post-secondary degree47 (34.2%)52 (65.8%)Speaks English or French most often267 (32.6%)553 (67.4%)Born in Canada244 (32.1%)517 (67.9%)aAll breast cancer patients are female.bAll prostate cancer patients are male.cOther category = patients aged 18–29 at diagnosis with a primary diagnosis of any invasive cancer, excluding: (1) stage IV at diagnosis (except for testicular cancer); (2) non-melanoma skin cancer; and (3) Kaposi’s sarcoma. Cohort characteristics in 823 patients diagnosed with cancer in Nova Scotia and who were 1–3 years post-treatment at the time of survey administration, stratified by sexual dysfunction concerns. aAll breast cancer patients are female. bAll prostate cancer patients are male. cOther category = patients aged 18–29 at diagnosis with a primary diagnosis of any invasive cancer, excluding: (1) stage IV at diagnosis (except for testicular cancer); (2) non-melanoma skin cancer; and (3) Kaposi’s sarcoma. Table 3 presents the results of the multivariable regression models for primary care use. Upon adjusted analyses, those with sexual dysfunction concerns had a 9% higher rate of primary care visits (all) during follow-up care compared to those without sexual dysfunction concerns (IRR = 1.09, 95% CI = 1.06–1.13, p < 0.0001) as well as an 11% higher rate of non-cancer visits (IRR = 1.11, 95% CI = 1.07–1.14, p < 0.0001). There were no statistical associations between cancer-related primary care visits and sexual dysfunction concerns (p = 0.994) nor was there an association between oncology visits during follow-up and sexual dysfunction concerns (p = 0.297) (see Table 4). The results did not change when the models were run for male and female separately. However, the IRRs for primary care visits in these separate models were greater for males than for females. See Supplemental File 1 for these results. Table 3Incidence Rate Ratios (adjusted analyses) for primary care visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded.VariablePrimary care visits (all)PoissonPrimary care visits (cancer related)PoissonPrimary care visits (non-cancer related)PoissonIRR [95% CI]IRR [95% CI]IRR [95% CI]Sexual dysfunction concerns (reference no concerns) 1.09 [1.06–1.13] 1.00 [0.81–1.24] 1.11 [1.07–1.14] Age at survey completion (reference age 55–64) Age 18–54 0.83 [0.79–0.87] 0.89 [0.65–1.20] 0.81 [0.77–0.86] Age 65–74 1.16 [1.12–1.20] 1.11 [0.88–1.40] 1.17 [1.13–1.21] Age > = 75 1.47 [1.42–1.53] 1.42 [1.07–1.88] 1.49 [1.43–1.56] Male sex (reference: female) 0.88 [0.84–0.92] 0.88 [0.64–1.20] 0.89 [0.85–0.93] Married or partnered (reference: not married or partnered)0.99 [0.96–1.02]1.17 [0.94–1.46]0.97 [0.94-1.00]Any chronic condition (reference: no chronic condition) 1.26 [1.22–1.31] 1.22 [0.93–1.59] 1.27 [1.22–1.31] Disease site (reference: other type) Hematological 0.79 [0.71–0.87] 0.44 [0.21–0.95] 0.88 [0.79–0.99] Breast 0.75 [0.69–0.82] 0.70 [0.37–1.32] 0.79 [0.71–0.87] Colorectal 0.80 [0.73–0.88] 0.74 [0.39–1.41] 0.84 [0.76–0.93] Melanoma 0.64 [0.59–0.71] 0.18 [0.09–0.37] 0.76 [0.68–0.84] Prostate 0.76 [0.70–0.84] 0.65 [0.34–1.25] 0.80 [0.73–0.89] Stage at diagnosis (reference: Stage I) Stage II1.00 [0.97–1.03]1.06 [086-1.31]0.99 [0.95–1.02]Stage III1.04 [1.01–1.08]1.12 [0.87–1.45]1.02 [0.98–1.06]Rural residence (reference: urban)0.91 [0.89–0.94]0.95 [0.78–1.15] 0.90 [0.87–0.93] Born in Canada (reference: not born in Canada)0.96 [0.91–1.01]0.96 [0.66–1.39] 0.95 [0.90-1.00] Highest education attained (reference: high school degree) Less than High school 1.19 [1.15–1.24] 1.08 [0.83–1.41] 1.21 [1.16–1.25] Some post-secondary 1.07 [1.03–1.10] 0.81 [0.63–1.04] 1.11 [1.07–1.16] Post-secondary certificate/diploma1.02 [0.99–1.06]0.94 [0.73–1.21]1.04 [0.99–1.08]Post-secondary degree0.99 [0.94–1.04] 0.63 [0.45–0.90] 1.04 [0.99–1.09]Speaks English or French most often (reference: does not speak English or French most often) 0.71 [0.59–0.86] 1.28 [0.29–5.62] 0.67 [0.55–0.81] Table 3Incidence Rate Ratios (adjusted analyses) for primary care visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded.VariablePrimary care visits (all)PoissonPrimary care visits (cancer related)PoissonPrimary care visits (non-cancer related)PoissonIRR [95% CI]IRR [95% CI]IRR [95% CI]Sexual dysfunction concerns (reference no concerns) 1.09 [1.06–1.13] 1.00 [0.81–1.24] 1.11 [1.07–1.14] Age at survey completion (reference age 55–64) Age 18–54 0.83 [0.79–0.87] 0.89 [0.65–1.20] 0.81 [0.77–0.86] Age 65–74 1.16 [1.12–1.20] 1.11 [0.88–1.40] 1.17 [1.13–1.21] Age > = 75 1.47 [1.42–1.53] 1.42 [1.07–1.88] 1.49 [1.43–1.56] Male sex (reference: female) 0.88 [0.84–0.92] 0.88 [0.64–1.20] 0.89 [0.85–0.93] Married or partnered (reference: not married or partnered)0.99 [0.96–1.02]1.17 [0.94–1.46]0.97 [0.94-1.00]Any chronic condition (reference: no chronic condition) 1.26 [1.22–1.31] 1.22 [0.93–1.59] 1.27 [1.22–1.31] Disease site (reference: other type) Hematological 0.79 [0.71–0.87] 0.44 [0.21–0.95] 0.88 [0.79–0.99] Breast 0.75 [0.69–0.82] 0.70 [0.37–1.32] 0.79 [0.71–0.87] Colorectal 0.80 [0.73–0.88] 0.74 [0.39–1.41] 0.84 [0.76–0.93] Melanoma 0.64 [0.59–0.71] 0.18 [0.09–0.37] 0.76 [0.68–0.84] Prostate 0.76 [0.70–0.84] 0.65 [0.34–1.25] 0.80 [0.73–0.89] Stage at diagnosis (reference: Stage I) Stage II1.00 [0.97–1.03]1.06 [086-1.31]0.99 [0.95–1.02]Stage III1.04 [1.01–1.08]1.12 [0.87–1.45]1.02 [0.98–1.06]Rural residence (reference: urban)0.91 [0.89–0.94]0.95 [0.78–1.15] 0.90 [0.87–0.93] Born in Canada (reference: not born in Canada)0.96 [0.91–1.01]0.96 [0.66–1.39] 0.95 [0.90-1.00] Highest education attained (reference: high school degree) Less than High school 1.19 [1.15–1.24] 1.08 [0.83–1.41] 1.21 [1.16–1.25] Some post-secondary 1.07 [1.03–1.10] 0.81 [0.63–1.04] 1.11 [1.07–1.16] Post-secondary certificate/diploma1.02 [0.99–1.06]0.94 [0.73–1.21]1.04 [0.99–1.08]Post-secondary degree0.99 [0.94–1.04] 0.63 [0.45–0.90] 1.04 [0.99–1.09]Speaks English or French most often (reference: does not speak English or French most often) 0.71 [0.59–0.86] 1.28 [0.29–5.62] 0.67 [0.55–0.81] Incidence Rate Ratios (adjusted analyses) for primary care visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded. Table 4Incidence Rate Ratios for oncology visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded.VariableOncology visitsNegative BinomialIRR [95% CI]Sexual dysfunction concerns (reference no concerns)1.17 [0.87–1.59] Age at Survey (reference age 55–64) Age 18–541.21 [0.80–1.84]Age 65–740.95 [0.69–1.32]Age > = 751.35 [0.91–2.01]Male sex (reference female)1.14 [0.73–1.79]Married or partnered (reference not married or partnered)0.95 [0.70–1.27]Any chronic condition (reference no chronic condition)1.19 [0.82–1.72] Disease site (reference: colorectal) Hematological1.36 [0.49–3.74]Breast0.68 [0.27–1.70]Other type 0.20 [0.08–0.49] Melanoma 0.17 [0.06–0.44] Prostate 0.31 [0.13–0.76] Stage at Diagnosis (reference: stage I) Stage II 1.48 [1.09–2.02] Stage III 2.67 [1.86–3.84] Rural residence (reference urban) 0.71 [0.54–0.92] Born in Canada (reference not born in Canada)0.63 [0.38–1.02] Highest Education attained (reference: high school degree) Less than High school1.08 [0.75–1.56]Some post-secondary0.95 [0.67–1.35]Post-secondary certificate/diploma0.85 [0.59–1.21]Post-secondary degree 0.47 [0.29–0.76] Speaks English or French most often (reference does not speak English or French most often)3.85 [0.43–34.13] Table 4Incidence Rate Ratios for oncology visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded.VariableOncology visitsNegative BinomialIRR [95% CI]Sexual dysfunction concerns (reference no concerns)1.17 [0.87–1.59] Age at Survey (reference age 55–64) Age 18–541.21 [0.80–1.84]Age 65–740.95 [0.69–1.32]Age > = 751.35 [0.91–2.01]Male sex (reference female)1.14 [0.73–1.79]Married or partnered (reference not married or partnered)0.95 [0.70–1.27]Any chronic condition (reference no chronic condition)1.19 [0.82–1.72] Disease site (reference: colorectal) Hematological1.36 [0.49–3.74]Breast0.68 [0.27–1.70]Other type 0.20 [0.08–0.49] Melanoma 0.17 [0.06–0.44] Prostate 0.31 [0.13–0.76] Stage at Diagnosis (reference: stage I) Stage II 1.48 [1.09–2.02] Stage III 2.67 [1.86–3.84] Rural residence (reference urban) 0.71 [0.54–0.92] Born in Canada (reference not born in Canada)0.63 [0.38–1.02] Highest Education attained (reference: high school degree) Less than High school1.08 [0.75–1.56]Some post-secondary0.95 [0.67–1.35]Post-secondary certificate/diploma0.85 [0.59–1.21]Post-secondary degree 0.47 [0.29–0.76] Speaks English or French most often (reference does not speak English or French most often)3.85 [0.43–34.13] Incidence Rate Ratios for oncology visits during follow-up care, defined as the 1–4 year time period following cancer diagnosis. Significant (p < 0.05) results are bolded. Discussion Even though sexual dysfunction is a known prevalent concern for many people after completing cancer treatment, relatively little attention has been paid to how people address these concerns and the extent to which sexual dysfunction impacts healthcare use. In this study, we examined whether sexual dysfunction was associated with physician use during routine follow-up care after completing cancer treatment. We found that sexual dysfunction can be an ongoing effect for cancer survivors during the early follow-up care period (1–3 years post-treatment), particularly for survivors of certain cancer types (e.g., prostate cancer). We also found those who reported sexual dysfunction concerns visited their primary care provider more in the first four years of follow-up care than those who reported no concerns in this area. These findings are important in the primary care context, given that cancer survivors are increasingly discharged to primary care after cancer treatment34. As a result, primary care providers are the main providers responsible for supporting survivors as they recover from their illness and resulting side-effects. The prevalence of sexual dysfunction in cancer survivors is reported to range from 30 to 100%5,6. Our finding is on the lower end of that reported elsewhere, albeit this may be related to the wording of the survey question, which did not ask about prevalence but rather whether sexual dysfunction was a concern for the respondent. Still, the literature demonstrates that sexual dysfunction remains a concern for many people long into the survivorship phase if it is not identified and managed with appropriate services and supports. In fact, an Australian study found that prostate cancer survivors continue to have high unmet needs in sexual function 15 years after completing treatment, with 87.2% of those who reported ongoing issues with sexual function describing this need as moderate/severe11. For many individuals, sexual dysfunction concerns become interconnected with psychosocial concerns, and lead to poorer quality of life and challenges with optimal recovery5,35. Yet, evidence-based interventions exist, for both males and females, to address challenges with sexual response as well as challenges with sexual desire and motivation5,36,37. In this study, respondents who reported concerns with sexual dysfunction visited their primary care providers more often during the follow-up period than those who did not report these same challenges. There is limited, if any, evidence to compare our findings. Researchers have found that both oncologists and primary care providers infrequently initiate conversations on sexual dysfunction with their cancer survivor patients20–23,27. For example, 80% of surveyed gyne-oncologists reported there was not enough time to discuss sexual health with their patients during appointments26. Similarly, a survey of primary care providers found that > 60% said they never or rarely discuss sexual dysfunction issues with their cancer survivor patients27. However, a U.S. survey of oncologists and primary care providers to explore their follow-up practices found that 43.4% and 24.6% of oncologists and primary care providers, respectively, feel that treating the sexual dysfunction concerns of cancer survivors is a shared responsibility38. Often cited barriers include limited time and lack of resources and training to support these conversations28–30,39,40. Given the higher primary care use in those who report concerns around sexual dysfunction, the primary care setting presents an opportunity to ask about sexual dysfunction and to refer to appropriate supports and services, if needed. Indeed, cancer survivors in Canada and elsewhere report that primary care providers play an important role in their post-treatment care, and that they value the care they receive in this setting – yet some still voice concerns around their primary care providers’ knowledge and training with respect to cancer-related side-effects41–45. Primary care providers should be supported to the extent possible, with suitable education around sexual health and access to appropriate resources and services, to optimize survivors’ sexual health and recovery after cancer. In Canada, the True North Sexual Health and Rehabilitation eTraining Program is an example of a program to train healthcare providers (e.g., physicians, nurses, psychologists, and allied health professionals) in sexual health and prostate cancer recovery, and has been found to increase their self-efficacy in this area46. It is possible that people who identify sexual dysfunction concerns have different health-seeking behaviors than people who do not report such concerns, accounting for the higher physician visits. Unfortunately, the dataset for this study did not provide an indication of why patients are interacting with the health system, other than for “cancer-related” or “other” reasons. Therefore, we do not have data to determine the precise reasons driving these visits. Much research has found that many different factors, including age, gender, income, ethnicity, cultural background, knowledge of one’s disease, and availability of healthcare services, influence health-seeking behaviors in people with cancer and other chronic conditions47. Still, research has found that relatively few people who identify sexual dysfunction issues after cancer actually seek professional help for their concerns48. In the larger, Pan-Canadian Cancer Transitions Study (of which this dataset is a subset), only 40% of those with a sexual dysfunction concern reported seeking help3. Of those who did not seek help, approximately one-third indicated they did not because someone told it was normal to expect and they did not believe anything could be done about their concern. The result is likely substantial unmet need around this prevalent ongoing effect. This study has several strengths. The first is the linkage of two disparate data sources: a survey dataset and administrative health databases. This allowed us to capture information on patient needs and experiences as well as comprehensive and longitudinal information on physician use. A second strength was that disease and diagnosis data were captured through the NSCR, alleviating the need to rely on self-report surveys for this information. The NSCR is a population-based cancer registry that has been mandated by law since 1964 to record all cancer diagnoses in the province. It also adheres to the North American Association of Central Cancer Registries standards to ensure consistency in data collection and data completeness49. Nonetheless, the study also has several limitations. First and foremost, the survey was not validated. However, it was based on two previously validated surveys31,32 and underwent extensive development and testing, including pilot testing with > 100 pilot participants, before study administration. Second, concerns about sexual dysfunction were assessed using a single, non-validated question, which did not allow us to assess the varied aspects of sexual dysfunction. However, comprehensive assessment of sexual dysfunction was not the purpose of the survey. Rather, the survey asked respondents about many different needs post-treatment, ranging from fatigue, lymphedema, insomnia, gastrointestinal issues, depression, anxiety, social functioning, return to work/school, health insurance, among others; the use of validated measures to assess each of these needs would have been impractical from a respondent burden perspective. Third, the datasets do not align directly with respect to their respective time periods. Specifically, sexual dysfunction concerns were captured 1–3 years after treatment completion, yet physician visits (the outcomes) were captured 1–4 years after cancer diagnosis. This is not ideal, yet the findings still demonstrate an association between concerns about sexual dysfunction and primary care use during respondents’ follow-up care. Related, patients with some cancer types, particularly Acute Lymphoblastic Leukemia, may have still been on treatment (maintenance phase) during the first year or two of our defined follow-up care period. Fourth, administrative health data in Nova Scotia only capture physician visits and not visits to other healthcare providers (e.g., nurses, counsellors, physiotherapists, pharmacists, and social workers). We know that these non-physician providers also play important roles in peoples’ care after cancer treatment. Fifth, we were unable to determine the specific reasons for visits in those who reported sexual dysfunction. Finally, this study may not be generalizable to the population of cancer survivors since we employed a complete case approach to analyses and excluded people diagnosed with stage IV cancers (except for testicular). Related to the latter, advances in novel therapies (e.g., targeted therapies and immunotherapies) mean that many people diagnosed with a stage IV cancer today live long-term with their disease. These individuals may also experience sexual health concerns, yet the findings of this study may not be generalizable to this growing population due to our exclusion criterion. In conclusion, we found that sexual dysfunction concerns were prevalent amongst cancer survivors who are 1–3 years post-treatment, through the percentage of people reporting concerns ranged widely across cancer types. Cancer survivors who reported moderate to high sexual dysfunction concerns had higher primary care use during the follow-up care period compared to survivors who reported no or low sexual dysfunction concerns. These findings highlight a potentially important role for primary care providers in addressing sexual health concerns during follow up care. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1